Title : Using PARP Inhibitors in Advanced Ovarian Cancer.

Pub. Date : 2018 Jul 15

PMID : 30080919






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 More recently, these two and a third PARP inhibitor, niraparib, were approved by the FDA as maintenance therapy following platinum-based chemotherapy for recurrent ovarian cancer. Platinum poly(ADP-ribose) polymerase 1 Homo sapiens